EPISTENT
This article was originally published in The Gray Sheet
Executive Summary
One year angiographic substudy results show up to a 60% decrease in mortality for patients randomized to stent placement plus abciximab over patients randomized to stent plus placebo or angioplasty with abciximab, reports Michael Lincoff, MD, Cleveland Clinic, at a Nov. 9 AHA press conference. Commenting on the 900-patient substudy, Lincoff noted: "Mortality is generally something we don't see a significant difference in trials this size because unfortunately death occurs frequently in this population of patients." The substudy hoped to cover as broad a clinical population as possible, he noted. Lincoff reported statistically significant mortality results of 2.4% for the placebo+stent group, 2.1% for the angioplasty+abciximab group, and 1.0% in stent +abciximab group
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.